Analysts Maintain Positive Outlook on e.l.f. Beauty Stock
JPMorgan and TD Cowen analysts reaffirm optimistic ratings for e.l.f. Beauty Inc., citing sales growth and favorable market conditions despite a target price adjustment.
Author
Latest reporting and analysis by Zackery Mayert.
JPMorgan and TD Cowen analysts reaffirm optimistic ratings for e.l.f. Beauty Inc., citing sales growth and favorable market conditions despite a target price adjustment.
Oil prices edged higher at the end of a volatile week as tensions in Iran and broader market sentiment influenced trading. Brent crude traded above $64 a barrel after a sharp drop, with reports indicating reduced immediate U.S. military action but continued regional deployments.
AI stocks led market gains in 2025, with ETFs like Global X AI & Technology, iShares AI Innovation, and Defiance Quantum offering diversified exposure beyond the 'Magnificent Seven' for 2026.
Truist lowered Silgan Holdings' price target to $50 while maintaining a Buy rating. The company also announced a new $500 million share repurchase program through 2029.
U.S. mortgage rates fell sharply after President Trump ordered a $200 billion mortgage bond purchase. The Federal Housing Finance Agency confirmed Fannie Mae and Freddie Mac would execute the buys, with an initial $3 billion purchase reported. The average 30-year fixed rate dropped to 5.99% on Jan. 9. JPMorgan Chase analysts expressed skepticism about the plan's market impact.
An evaluation of AKC pet insurance shows high average costs and limited base policy coverage, requiring add-ons for comprehensive protection, though it covers preexisting conditions after one year.
Bitfarms executives detailed a strategic pivot from Bitcoin mining to HPC/AI data centers, citing power and infrastructure as key constraints. The company plans a 'build first, price later' approach, designs for NVIDIA's Vera Rubin GPUs, and expects key U.S. sites to reach construction approval in late 2026.
Alphatec Holdings announced preliminary 2025 financial results on January 12, showing 25% revenue growth and providing a 2026 outlook. The company also entered a strategic agreement with Theradaptive for exclusive U.S. distribution rights to OsteoAdapt.
Truist initiated coverage of Palantir with a Buy rating and $223 target, citing AI-driven growth, while RBC Capital reiterated a Sell rating with a $50 target.